<p>阿瑪琳公司（NASDAQ:AMRN - 獲取免費報告）在週五的交易中達到了新的 52 周低點。該股最低交易價格為 0.44 美元，最後交易價格為 9.11 美元，成交量為 1319852 股。該股此前收盤價為 0.46 美元。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>3 只生物技術股票正在獲得動力</li>
</ul>
<p>另外，StockNews.com 在週二開始對阿瑪琳的股票進行覆蓋。他們對該股給予了 “賣出” 評級。</p>
<p><strong>查看我們關於 AMRN 的最新研究報告</strong></p>
<h2>阿瑪琳股票表現</h2>
<ul>
<li>Ocugen 或阿瑪琳是否值得投資的便士股票？</li>
</ul>
<p>該公司的 50 日移動平均價格為 0.50 美元，200 日移動平均價格為 0.53 美元。該公司的市值為 37.4 億美元，市盈率為-98.89，貝塔值為 1.38。</p>
<p>阿瑪琳（NASDAQ:AMRN - 獲取免費報告）最近於 3 月 12 日（星期三）發佈了季度財報。這家生物製藥公司報告的每股收益為（2.40 美元），低於分析師一致預期的（1.20 美元），差距為（1.20 美元）。該公司季度收入為 6231 萬美元，而分析師預期為 3237 萬美元。阿瑪琳的股本回報率為-7.22%，淨利潤率為-16.33%。研究分析師預計阿瑪琳公司將在本年度發佈-0.15 美元的每股收益。</p>
<h2>阿瑪琳的機構交易</h2>
<ul>
<li>阿瑪琳在財報發佈後是否值得納入你的投資組合？</li>
</ul>
<p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。Arkfeld Wealth Strategies L.L.C.在第四季度將其在阿瑪琳的持倉增加了 52.6%。Arkfeld Wealth Strategies L.L.C.現在擁有 58000 股這家生物製藥公司的股票，價值 30000 美元，此前在該期間又購買了 20000 股。LCM Capital Management Inc 在第四季度將其在阿瑪琳的持倉增加了 3.1%。LCM Capital Management Inc 現在擁有 838259 股這家生物製藥公司的股票，價值 407000 美元，此前在上個季度又購買了 25100 股。LPL Financial LLC 在第四季度將其在阿瑪琳的持倉增加了 26.0%。LPL Financial LLC 現在擁有 153020 股這家生物製藥公司的股票，價值 74000 美元，此前在上個季度又購買了 31555 股。BNP Paribas Financial Markets 在第四季度將其在阿瑪琳的持倉增加了 3.0%。BNP Paribas Financial Markets 現在擁有 1340920 股這家生物製藥公司的股票，價值 650000 美元，此前在該期間又購買了 39452 股。最後，賓夕法尼亞州公共學校僱員退休系統在第四季度購買了阿瑪琳的新股份，價值約 36000 美元。22.25% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>阿瑪琳公司簡介</h2>
<p>（獲取免費報告）</p>
<p>阿瑪琳公司是一家制藥公司，專注於在美國、歐洲國家、加拿大、黎巴嫩和阿拉伯聯合酋長國開發和商業化治療心血管疾病的療法。該公司提供 VASCEPA，這是一種處方專用的 omega-3 脂肪酸產品，用於作為飲食的輔助治療，以降低嚴重高甘油三酯血癥成年患者的甘油三酯水平。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票超過阿瑪琳</li>
<li>股息之王寶潔在財報發佈後的疲軟中值得買入</li>
<li>火箭實驗室股票：經受住風暴，是時候反彈了？</li>
<li>5 個適合股息增長投資者的折扣機會</li>
<li>Snowflake 通過加倍投資 AI 來推動增長</li>
<li>如何使用股票篩選器找到股票</li>
<li>IAMGOLD 股票上漲，因轉型故事獲得關注</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在阿瑪琳嗎？</h2>
<p>在你考慮阿瑪琳之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而阿瑪琳並不在名單上。</p>
<p>雖然阿瑪琳目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

阿瑪琳

<p>阿瑪琳公司（NASDAQ:AMRN）在交易中達到了新的 52 周低點 0.44 美元，收盤價為 0.46 美元。分析師給予了 “賣出” 評級，市值為 37.4 億美元，每股收益為負 2.40 美元。該公司報告的收入為 6231 萬美元，超出預期。機構投資者增加了持股比例，對沖基金持有 22.25% 的股份。阿瑪琳專注於心血管疾病的治療，特別是用於降低甘油三酯水平的 VASCEPA</p>

<p>Amarin Co. plc (NASDAQ:AMRN - Get Free Report) reached a new 52-week low during trading on Friday . The stock traded as low as $0.44 and last traded at $9.11, with a volume of 1319852 shares. The stock had previously closed at $0.46.</p>
<div class="lb-trans"><p>阿瑪琳公司（NASDAQ:AMRN - 獲取免費報告）在週五的交易中達到了新的 52 周低點。該股最低交易價格為 0.44 美元，最後交易價格為 9.11 美元，成交量為 1319852 股。該股此前收盤價為 0.46 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>3 Biotech Stocks Gaining Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物技術股票正在獲得動力</li>
</ul>
</div><p>Separately, StockNews.com began coverage on shares of Amarin in a report on Tuesday. They issued a &#34;sell&#34; rating on the stock.</p>
<div class="lb-trans"><p>另外，StockNews.com 在週二開始對阿瑪琳的股票進行覆蓋。他們對該股給予了 “賣出” 評級。</p>
</div><p><strong>View Our Latest Research Report on AMRN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 AMRN 的最新研究報告</strong></p>
</div><h2>Amarin Stock Performance</h2>
<div class="lb-trans"><h2>阿瑪琳股票表現</h2>
</div><ul>
<li>Are Ocugen or Amarin Good Penny Stocks to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>Ocugen 或阿瑪琳是否值得投資的便士股票？</li>
</ul>
</div><p>The firm has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.53. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -98.89 and a beta of 1.38.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 0.50 美元，200 日移動平均價格為 0.53 美元。該公司的市值為 37.4 億美元，市盈率為-98.89，貝塔值為 1.38。</p>
</div><p>Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($1.20). The company had revenue of $62.31 million for the quarter, compared to analyst estimates of $32.37 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. Research analysts anticipate that Amarin Co. plc will post -0.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿瑪琳（NASDAQ:AMRN - 獲取免費報告）最近於 3 月 12 日（星期三）發佈了季度財報。這家生物製藥公司報告的每股收益為（2.40 美元），低於分析師一致預期的（1.20 美元），差距為（1.20 美元）。該公司季度收入為 6231 萬美元，而分析師預期為 3237 萬美元。阿瑪琳的股本回報率為-7.22%，淨利潤率為-16.33%。研究分析師預計阿瑪琳公司將在本年度發佈-0.15 美元的每股收益。</p>
</div><h2>Institutional Trading of Amarin</h2>
<div class="lb-trans"><h2>阿瑪琳的機構交易</h2>
</div><ul>
<li>Does Amarin Deserve a Spot in Your Portfolio after Earnings ?</li>
</ul>
<div class="lb-trans"><ul>
<li>阿瑪琳在財報發佈後是否值得納入你的投資組合？</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Arkfeld Wealth Strategies L.L.C. increased its position in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 20,000 shares during the period. LCM Capital Management Inc raised its position in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after purchasing an additional 25,100 shares during the last quarter. LPL Financial LLC grew its position in Amarin by 26.0% during the 4th quarter. LPL Financial LLC now owns 153,020 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 31,555 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Amarin by 3.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,340,920 shares of the biopharmaceutical company's stock valued at $650,000 after purchasing an additional 39,452 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Amarin in the fourth quarter valued at about $36,000. 22.25% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。Arkfeld Wealth Strategies L.L.C.在第四季度將其在阿瑪琳的持倉增加了 52.6%。Arkfeld Wealth Strategies L.L.C.現在擁有 58000 股這家生物製藥公司的股票，價值 30000 美元，此前在該期間又購買了 20000 股。LCM Capital Management Inc 在第四季度將其在阿瑪琳的持倉增加了 3.1%。LCM Capital Management Inc 現在擁有 838259 股這家生物製藥公司的股票，價值 407000 美元，此前在上個季度又購買了 25100 股。LPL Financial LLC 在第四季度將其在阿瑪琳的持倉增加了 26.0%。LPL Financial LLC 現在擁有 153020 股這家生物製藥公司的股票，價值 74000 美元，此前在上個季度又購買了 31555 股。BNP Paribas Financial Markets 在第四季度將其在阿瑪琳的持倉增加了 3.0%。BNP Paribas Financial Markets 現在擁有 1340920 股這家生物製藥公司的股票，價值 650000 美元，此前在該期間又購買了 39452 股。最後，賓夕法尼亞州公共學校僱員退休系統在第四季度購買了阿瑪琳的新股份，價值約 36000 美元。22.25% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Amarin Company Profile</h2>
<div class="lb-trans"><h2>阿瑪琳公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.</p>
<div class="lb-trans"><p>阿瑪琳公司是一家制藥公司，專注於在美國、歐洲國家、加拿大、黎巴嫩和阿拉伯聯合酋長國開發和商業化治療心血管疾病的療法。該公司提供 VASCEPA，這是一種處方專用的 omega-3 脂肪酸產品，用於作為飲食的輔助治療，以降低嚴重高甘油三酯血癥成年患者的甘油三酯水平。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Amarin</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Rocket Lab Stock: Weathering the Storm, Time for a Comeback?</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>Snowflake Boosts Growth by Doubling Down on AI</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>IAMGOLD Stock Climbs as Turnaround Story Gains Traction</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過阿瑪琳</li>
<li>股息之王寶潔在財報發佈後的疲軟中值得買入</li>
<li>火箭實驗室股票：經受住風暴，是時候反彈了？</li>
<li>5 個適合股息增長投資者的折扣機會</li>
<li>Snowflake 通過加倍投資 AI 來推動增長</li>
<li>如何使用股票篩選器找到股票</li>
<li>IAMGOLD 股票上漲，因轉型故事獲得關注</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amarin Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在阿瑪琳嗎？</h2>
</div><p>Before you consider Amarin, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮阿瑪琳之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而阿瑪琳並不在名單上。</p>
</div><p>While Amarin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然阿瑪琳目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

阿瑪琳（NASDAQ:AMRN）創下 12 個月新低 - 接下來會如何發展？